American Registry of Pathology Expert Opinions: Evaluation of poorly differentiated malignant neoplasms on limited samples - Gastrointestinal mucosal biopsies

Andrew M Bellizzi; Elizabeth A Montgomery; Jason L Hornick

doi:10.1016/j.anndiagpath.2019.151419

Back

American Registry of Pathology Expert Opinions: Evaluation of poorly differentiated malignant neoplasms on limited samples - Gastrointestinal mucosal biopsies

Journal article

Open access

Peer reviewed

American Registry of Pathology Expert Opinions: Evaluation of poorly differentiated malignant neoplasms on limited samples - Gastrointestinal mucosal biopsies

Andrew M Bellizzi, Elizabeth A Montgomery and Jason L Hornick

Annals of diagnostic pathology, Vol.44, pp.151419-151419

02/2020

DOI: 10.1016/j.anndiagpath.2019.151419

PMID: 31786484

Files and links (1)

url

https://doi.org/10.1016/j.anndiagpath.2019.151419View

Published (Version of record) Open Access

Abstract

This review reflects a collaboration between the American Registry of Pathology (the publisher of the Armed Forces Institute of Pathology Fascicles) and Annals of Diagnostic Pathology. It is part of a series of expert recommendations on topics encountered in daily practice. The authors, three pathologists with expertise in gastrointestinal tract pathology and immunohistochemistry, met on 30 July 2019 tasked with developing expert recommendations for evaluating poorly differentiated and undifferentiated malignant neoplasms encountered on mucosal biopsies of the gastrointestinal tract. We focused on esophageal, gastric, small intestinal, colorectal, and anal (i.e., tubal gut) samples. When faced with diagnostic uncertainty on the initial H&E, it is best to begin by trying to assign the broad tumor class with screening markers such as pankeratin, S100 protein or SOX10, and CD20 or CD45. Once a broad tumor class is established, more specific differentiation markers can be pursued (e.g., lineage-restricted transcription factors for adenocarcinoma; p40 for squamous cell carcinoma; chromogranin A and synaptophysin or INSM1 for neuroendocrine neoplasms). Every small biopsy containing tumor should be considered a potential molecular pathology sample; cutting extra unstained slides with this testing in mind is strongly encouraged.

Immunohistochemistry

Differential diagnosis

Site of origin

Tumor classification

Details

Title: Subtitle: American Registry of Pathology Expert Opinions: Evaluation of poorly differentiated malignant neoplasms on limited samples - Gastrointestinal mucosal biopsies
Creators: Andrew M Bellizzi - University of Iowa Hospitals and Clinics
Elizabeth A Montgomery - Johns Hopkins University
Jason L Hornick - Brigham and Women's Hospital
Resource Type: Journal article
Publication Details: Annals of diagnostic pathology, Vol.44, pp.151419-151419
DOI: 10.1016/j.anndiagpath.2019.151419
PMID: 31786484
NLM abbreviation: Ann Diagn Pathol
ISSN: 1092-9134
eISSN: 1532-8198
Publisher: Elsevier Inc
Language: English
Date published: 02/2020
Academic Unit: Pathology
Record Identifier: 9984185181102771

Metrics

25 Record Views

8 Times Cited - Web of Science